Session Information
Date: Monday, June 20, 2016
Session Title: Epidemiology
Session Time: 12:30pm-2:00pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: To estimate the risk of incident cancer; any type and specific types in PD (Parkinson’s disease) patients, by sex; and to compare it to the risk in the general population; In a large-scale cohort study.
Background: PD patients were shown to have a differential risk of different type of cancers. Data on this association may improve the understanding of the etiology and pathogenesis of PD.
Methods: Using BIG-DATA approach: The PD population-based retrospective cohort included 7125 new patients, for the period 1.1.2000 to 31.12.2012 (study period); based on drugs purchases database of Maccabi Health Services (MHS). Information on incident cancer during this period was derived from MHS cancer registry. We used K-M curves to estimate time to cancer event. Standardized Incidence Ratios (SIRs) accounting for age, chronological year and sex were calculated to compare incident cancers among PDs to that of MHS population.
Results: The PD cohort included 54% men, with mean age of first treatment 71.2 years (sd=10.3), in a time-window of 7 years before first treatment and 3.5 years after that: 21% men and 15% women were diagnosed with incident cancer.
Men (n=3828) | Women (n=3297) | ||
Age at 1st APD purchase(mean ± SD) | 71.1 ± 10.6 | 71.5 ± 10.7 | |
Follow-up time (yrs) (mean ± SD) | 10.4 ± 3.5 | 10.9 ± 3.2 | |
Person years | 43710 | 38190 | |
Time (yrs) before 1st APD purchase (mean ± SD) | 6.67 ± 3.6 | 6.40 ± 3.6 | |
Time (yrs) after 1st APD purchase (years ± SD) | 3.69 ± 4.0 | 4.49 ± 3.8 | |
Incident Cancer comorbidity (%) | 21.0 | 15.1 | |
Comorbidities except for cancer | |||
CHF (%) | 12.4 | 9.7 | |
MI (%) | 8.5 | 7.2 | |
Stroke (%) | 16.3 | 11.7 | |
TIA (%) | 5.9 | 4.3 | |
Atrial fibrillation (%) | 15.6 | 13.2 | |
HTN (%) | 40.1 | 47.2 | |
Deceased (%) | 36.0 | 31.2 |
Cancer type (ICD-9) | Males | Females | ||
N | SIR (95% CI) | N | SIR (95% CI) | |
Any type (140-239) | 804 | 0.99 (0.92-1.06) | 498 | 0.98 (0.89-1.07) |
Breast (174-175) | 127 | 1.15 (0.95-1.36) | ||
Colon (153) | 43 | 0.53 (0.42-0.78) | 27 | 0.58 (0.35-0.77) |
CNS (191-192) | 4 | 0.77 (0.21-1.97) | 2 | 0.45 (0.05-1.61) |
Kidney (189) | 23 | 1.06 (0.67-1.59) | 5 | 0.56 (0.18-1.32) |
Leukemia (204-208) | 14 | 0.7 (0.38-1.18) | 9 | 0.89 (0.41-1.70) |
Lung (162) | 19 | 0.35 (0.21-0.54) | 11 | 0.52 (0.26-0.94) |
Lymphoma (200-202) | 31 | 1.03 (0.70-1.46) | 16 | 0.74 (0.42-1.20) |
Melanoma (172) | 25 | 0.92 (0.60-1.36) | 19 | 1.08 (0.65-1.69) |
Ovary (183) | 5 | 0.46 (0.15-1.08) | ||
Pancreas (157) | 2 | 0.15 (0.02-0.54) | 11 | 0.85 (0.42-1.52) |
Prostate (185) | 200 | 0.99 (0.86-1.14) | ||
Rectum (154) | 15 | 1.06 (0.68-1.56) | 11 | 0.77 (0.39-1.38) |
Thyroid (193) | 7 | 1.59 (0.64-3.27) | 8 | 0.93 (0.40-1.84) |
Conclusions: Our big-data analysis found no difference in the risk of any-type of cancer among PDs compared to the general population in contrast to some previous findings, but we focused in a certain time-window. Specifically, lung cancer and colon lower risks findings are in line with previous studies. The non-increased breast cancer and melanoma risks findings somewhat differ from previous studies. More large-scale data linkage studies are needed to explore cancer comorbidity among PDs in different time windows to shed more light on this association.
To cite this abstract in AMA style:
R. Gurel, N. Giladi, V. Rozani, T. Gurevich, B. El-Ad, B. Hemo, J. Tsamir, C. Peretz. Cancer comorbidity among PD patients; a population based large-scale cohort study [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/cancer-comorbidity-among-pd-patients-a-population-based-large-scale-cohort-study/. Accessed November 22, 2024.« Back to 2016 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/cancer-comorbidity-among-pd-patients-a-population-based-large-scale-cohort-study/